Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis

Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis

Two short-course bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (TB) showed “robust evidence” for superior efficacy and less ototoxicity compared to a 9-month injectable control regimen, researchers report. The findings validate the World Health Organization’s (WHO’s) current recommendation of a 9-month,…

Read More